Junshi Biosciences' Toripalimab Application Accepted by Australia’s TGA

For the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and for toripalimab, as a single agent...

December 04, 2023 | Monday | News
FDA Approves Agilent's PD-L1 IHC 22C3 pharmDx for Gastric Adenocarcinoma

Agilent  announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Ga...

November 29, 2023 | Wednesday | News
Mesoblast Seeks Orphan Drug Status for Rexlemestrocel-L in Treating Severe Congenital Heart Disease

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it has filed for orphan ...

November 27, 2023 | Monday | News
Junshi Biosciences' VV116 COVID-19 Treatment Hits Lancet Infectious Diseases in Phase 3 Study Results

The paper presents final analysis results from a multicenter, double-blind, phase 3, randomized controlled study (NCT05582629) evaluating the efficacy and ...

November 24, 2023 | Friday | News
Genentech, NVIDIA Partner for Strategic AI Collaboration in Drug Discovery

- Collaboration leverages expertise in artificial intelligence from Genentech and NVIDIA to unlock scientific innovation and empower R&D at a sca...

November 22, 2023 | Wednesday | News
Certara Launches Simcyp™ Software to Enhance Drug Formulation Efficiency

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation,  announced the introduction of Simcyp™ Biopharmaceutics software. It is designed...

November 22, 2023 | Wednesday | News
Hovione Acquires ExtremoChem for Enhanced Biopharmaceutical Stabilization and Delivery

Hovione has acquired ExtremoChem Lda, a start-up company with a portfolio of rare sugars, synthetic analogues of the natural molecules found in extremoph...

November 21, 2023 | Tuesday | News
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

"The NMPA approval of vebreltinib is an important milestone toward providing a new treatment option for patients with MET exon 14 skipping NSCLC in China. ...

November 17, 2023 | Friday | News
Vertex and CRISPR Therapeutics Granted Historic Approval for CASGEVY™, the World's First CRISPR/Cas9 Gene-Edited Therapy, by UK MHRA to Combat Sickle Cell Disease and Beta Thalassemia

 - First regulatory authorization of a CRISPR-based gene-editing therapy in the world – - CASGEVY is indicated for the treatment of sickle cell...

November 17, 2023 | Friday | News
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneou...

November 14, 2023 | Tuesday | News
Charles River and Aitia Partner to Advance Logica in Neurodegenerative and Oncology Discoveries

Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an eq...

November 14, 2023 | Tuesday | News
STADA, Alvotech Get Positive CHMP Nod for Europe's First Ustekinumab Biosimilar to Stelara

Positive CHMP opinion for Uzpruvo biosimilar is based on comprehensive package comprising analytical, non-clinical and clinical similarity data, includin...

November 13, 2023 | Monday | News
FDA Prioritizes Bristol Myers Squibb's Breyanzi for CLL/SLL Review

Application based on results from TRANSCEND CLL 004, the first pivotal multicenter trial to show clinical benefit with a CAR T cell therapy in heavil...

November 10, 2023 | Friday | News
Bayer and Recursion focus research collaboration on Oncology

Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients Drug discovery research coll...

November 10, 2023 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close